The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood-Reference-Cited by-同舟云学术

The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood

Published:2019-07-26 Issue:11 Volume:37 Page:1305-1312
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Kent Seamus^ORCID,Becker Frauke,Feenstra Talitha,Tran-Duy An,Schlackow Iryna,Tew Michelle,Zhang Ping,Ye Wen,Lizheng Shi,Herman William,McEwan Phil,Schramm Wendelin,Gray Alastair,Leal Jose,Lamotte Mark,Willis Michael,Palmer Andrew J,Clarke Philip

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-019-00825-1.pdf

Reference34 articles.

1. Goldacre B. The WHO joint statement from funders on trials transparency. BMJ. 2017;357:j2816. https://doi.org/10.1136/bmj.j2816 .

2. Easterbrook PJ, Gopalan R, Berlin JA, et al. Publication bias in clinical research. Lancet. 1991;337:867–72. https://doi.org/10.1016/0140-6736(91)90201-Y .

3. Ioannidis JPA. Why most clinical research is not useful. PLoS Med. 2016;13:e1002049. https://doi.org/10.1371/journal.pmed.1002049 .

4. Chalmers I, Glasziou P, Godlee F. All trials must be registered and the results published. BMJ. 2013;346:f105. https://doi.org/10.1136/bmj.f105 .

5. Watson M. When will ‘open science’ become simply ‘science’? Genome Biol. 2015;16:101. https://doi.org/10.1186/s13059-015-0669-2 .

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘Managing values’ in health economics modelling: Philosophical and practical considerations;Social Science & Medicine;2024-10

2. Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge;Value in Health;2024-07

3. Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management;PharmacoEconomics;2024-06-26

4. Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data;PharmacoEconomics;2024-06-21

5. A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening;Applied Health Economics and Health Policy;2024-05-16